CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Hydroxychloroquine sulfateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1499 Mindfulness Rounds Wiki 1.00
drug1372 Lopinavir/ritonavir Wiki 0.32

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is no clinical studies on the reduction of viral load in patients with COVID-19. This study investigate whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from respiratory specimen in patients with mild COVID-19.

NCT04307693 COVID-19 Drug: Lopinavir/ritonavir Drug: Hydroxychloroquine sulfate
MeSH:Coronavirus Infections

Primary Outcomes

Description: Area under the curve (AUC) of Ct value or viral copies number per mL

Measure: Viral load

Time: hospital day 3, 5, 7, 10, 14, 18

Secondary Outcomes

Description: Viral load change (log10 viral load assessed by reverse transcription-PCR) during hospital day 3, 5, 7, 10, 14, 18)

Measure: Viral load change

Time: hospital day 3, 5, 7, 10, 14, 18

Description: Time to clinical improvement (TTCI) is defined as the time to normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough within at least 72 hours

Measure: Time to clinical improvement (TTCI)

Time: up to 28 days

Description: Percentage of progression to supplemental oxygen requirement by day 7

Measure: Percentage of progression to supplemental oxygen requirement by day 7

Time: hospital day 7

Description: Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7

Measure: Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7

Time: hospital day 7

Description: Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission

Measure: Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission

Time: up to 28 days

Description: Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7

Measure: Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7

Time: hospital day 7

Description: Safety and tolerability, as assessed by adverse effects

Measure: adverse effects

Time: up to 28 days

Description: Concentration of Lopinavir/ritonavir and hydroxychloroquine

Measure: Concentration of Lopinavir/ritonavir and hydroxychloroquine

Time: 1, 2, 4, 5, 12 hours after taking intervention medicine


No related HPO nodes (Using clinical trials)